HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead.
At HOOKIPA we are united by a set of core values and common beliefs which give meaning to our work and guide our daily behaviour.
How we see the future:
In the future, we envision a world in which medicines reinforce the natural ability of the body to prevent and cure serious diseases.
What we do:
We work to reprogram the immune system to more effectively combat cancer and infectious diseases.
What drives us:
We want to eliminate the suffering of patients with specific and severe medical problems, and while doing so, we want to grow as individuals, professionally and personally.
How we work:
We go for it, and we never give up.
How we collaborate:
We thrive on our differences.
We fight for innovation.
We challenge ourselves to act authentically and transparently.